Bay Street News

Immunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference

NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) — Immunovant, Inc. (NASDAQ: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, announced today that Pete Salzmann, Chief Executive Officer, will provide a corporate overview at the SVB Leerink 9th Annual Global Healthcare Conference, taking place February 25-27 in New York City.
About Immunovant, Inc.
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Contact:
John Strumbos, Ph.D., MBA
Vice President, Finance
Immunovant, Inc.
info@immunovant.com
 

Bay Street News